Regeneron Pharma (REGN) PT Raised to $600 at Baird on Strong Eylea Data
Tweet Send to a Friend
Baird analyst Brian Skorney raised the price target on Regeneron Pharma (NASDAQ: REGN) to $600.00 (from $510.00) after procuring a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
